As mutant KRAS can interfere with siRNA-mediated gene silencing in pancreatic cancer cells, the presence of KRAS mutations in EGI-1 cell lines could have resulted in impaired siRNA-mediated gene silencing. Here, KRAS is linked to pancreatic neoplasm.